BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34954618)

  • 1. Molecular hybridization used to design and synthesize neo-tanshinlactone derivatives as PD-1/PD-L1 inhibitors.
    Zhang M; Liu J; Wang Y; Wang P; Morris-Natschke S; Lee KH
    Bioorg Med Chem; 2022 Jan; 54():116579. PubMed ID: 34954618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and structure-activity relationship of programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing a benzo[d]isothiazole scaffold.
    Chen H; Wang K; Yang Y; Huang X; Dai X; Feng Z
    Eur J Med Chem; 2021 May; 217():113377. PubMed ID: 33770574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
    Yang Y; Wang K; Chen H; Feng Z
    Eur J Med Chem; 2021 Feb; 211():113001. PubMed ID: 33272783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and structure-activity relationship of PD-1/PD-L1 inhibitors with a benzo[d]isoxazole scaffold.
    Huang X; Chen H; Dai X; Xu M; Wang K; Feng Z
    Bioorg Med Chem Lett; 2021 Nov; 52():128403. PubMed ID: 34610423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
    Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
    Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[
    Liu L; Yao Z; Wang S; Xie T; Wu G; Zhang H; Zhang P; Wu Y; Yuan H; Sun H
    J Med Chem; 2021 Jun; 64(12):8391-8409. PubMed ID: 34115499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis, and Pharmacological Evaluation of Biaryl-Containing PD-1/PD-L1 Interaction Inhibitors Bearing a Unique Difluoromethyleneoxy Linkage.
    Song Z; Liu B; Peng X; Gu W; Sun Y; Xing L; Xu Y; Geng M; Ai J; Zhang A
    J Med Chem; 2021 Nov; 64(22):16687-16702. PubMed ID: 34761679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationship and biological evaluation of 12 N-substituted aloperine derivatives as PD-L1 down-regulatory agents through proteasome pathway.
    Zeng QX; Wang K; Zhang X; Shi YL; Dou YY; Guo ZH; Zhang XT; Zhang N; Deng HB; Li YH; Song DQ
    Bioorg Chem; 2021 Dec; 117():105432. PubMed ID: 34678602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.
    Gao T; Mao Z; Li W; Pei R
    J Mater Chem B; 2021 Jan; 9(3):746-756. PubMed ID: 33319876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel CA-4 analogs as dual inhibitors of tubulin polymerization and PD-1/PD-L1 interaction for cancer treatment.
    Yang X; Cheng B; Xiao Y; Xue M; Liu T; Cao H; Chen J
    Eur J Med Chem; 2021 Mar; 213():113058. PubMed ID: 33280898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, Synthesis, and Evaluation of
    OuYang Y; Gao J; Zhao L; Lu J; Zhong H; Tang H; Jin S; Yue L; Li Y; Guo W; Xu Q; Lai Y
    J Med Chem; 2021 Jun; 64(11):7646-7666. PubMed ID: 34037385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1.
    Cheng B; Ren Y; Cao H; Chen J
    Eur J Med Chem; 2020 Aug; 199():112377. PubMed ID: 32388281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of novel quinazoline derivatives as immune checkpoint inhibitors.
    Thuy Lu Vo T; Hoang VH; Thi Phuong Dung P; Anh Chi N; Minh Huy V; Tung Ngo S; Thi Kim Nguyen Y; Thi Thu Hien T; Hoang TH; Thi Do Y; Hae Seo J; Tran PT
    Bioorg Med Chem Lett; 2024 Aug; 108():129796. PubMed ID: 38754563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment.
    Cheng B; Wang W; Niu X; Ren Y; Liu T; Cao H; Wang S; Tu Y; Chen J; Liu S; Yang X; Chen J
    J Med Chem; 2020 Dec; 63(24):15946-15959. PubMed ID: 33264007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Stone Guest: How Does pH Affect Binding Properties of PD-1/PD-L1 Inhibitors?
    Riccio A; Coletti A; Dolciami D; Mammoli A; Cerra B; Moretti S; Gioiello A; Ferlin S; Puxeddu E; Macchiarulo A
    ChemMedChem; 2021 Feb; 16(3):568-577. PubMed ID: 33085193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis, and Biological Evaluation of Linear Aliphatic Amine-Linked Triaryl Derivatives as Potent Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction with Promising Antitumor Effects In Vivo.
    Guo J; Luo L; Wang Z; Hu N; Wang W; Xie F; Liang E; Yan X; Xiao J; Li S
    J Med Chem; 2020 Nov; 63(22):13825-13850. PubMed ID: 33186040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and pharmacological evaluation of novel resorcinol biphenyl ether analogs as small molecule inhibitors of PD-1/PD-L1 with benign toxicity profiles for cancer treatment.
    Cao H; Cheng B; Liu T; Chen J
    Biochem Pharmacol; 2021 Jun; 188():114522. PubMed ID: 33741334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of quinazoline derivatives as novel small-molecule inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
    Wang Y; Kun Huang ; Gao Y; Yuan D; Ling L; Liu J; Wu S; Chen R; Li H; Xiong Y; Liu H; Ma J
    Eur J Med Chem; 2022 Feb; 229():113998. PubMed ID: 34839997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Novel Small-Molecule-Based Potential PD-L1/EGFR Dual Inhibitors with High Druggability for Glioblastoma Immunotherapy.
    Yang Z; Liu Z; Wan S; Xu J; Huang Y; He H; Liu T; Li L; Ren Y; Zhang J; Chen J
    J Med Chem; 2024 May; 67(10):7995-8019. PubMed ID: 38739112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.